Clinical trial · Observational
Medium Dose of Cytarabine and Mitoxantrone
The Clinical Observationg on HAM for Acute Myeloid Leukemia
NCT04024241CI-TRIAL-00039547HAMunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
By observation of the inpatients in shenzhen people's hospital,research the curative effect of the two chemotherapy schemes on AML-High dose of cytarabine and HAM.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myelogenous Leukemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytarabine | Drug | Cytarabine | ALIAS |
| Flow Cytometer | Device | — | UNRESOLVED |
| Mitoxantrone | Drug | Mitoxantrone | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- high dose of cytarabine
- description
- high dose of cytarabine
- interventionNames
- Device: Flow Cytometer
- Drug: Mitoxantrone
- Drug: Cytarabine
- label
- HAM
- description
- medium dose of cytarabine and mitoxantrone
- interventionNames
- Device: Flow Cytometer
- Drug: Mitoxantrone
- Drug: Cytarabine
Primary outcomes (2)
- measure
- bone marrow suppression time
- timeFrame
- one month
- description
- time of agranulocytosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: people diagnosed as AML Exclusion Criteria: * acute promyeloytic leukemia
References
Publications (0)
Data not yet available
No reference posted for this study.